Health and Healthcare
Short Sellers Grow More Selective on Major Biotechs
Published:
Last Updated:
The short interest data are out for the most recent settlement date, October 31. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside. Now that the U.S. presidential election is over and Hillary Clinton is somewhat out of the picture, major biotech companies can breathe a little easier knowing that the pressure is off, if for just now at least.
As we have said before, FDA rulings can make or break the biotech sector, and short sellers and mega-bulls often go to war against each other in these companies. After all, if a single failed clinical trial can mean disaster for a stock, then some short sellers can argue for a stock implosion down the road.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The October 31 short interest data have been compared with the previous report, and short interest moves in these selected biotech stocks were relatively flat.
Amgen Inc. (NASDAQ: AMGN) saw its short interest decrease to 7.38 million shares from the previous level of 7.91 million. Shares closed most recently at $146.42, in a 52-week trading range of $133.64 to $176.85.
Biogen Inc. (NASDAQ: BIIB) had its short interest decrease slightly to 2.36 million shares from the previous 2.55 million. The stock closed Wednesday at $319.86, within a 52-week range of $223.02 to $333.65.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased barely to 9.26 million shares from the previous 8.99 million. Shares closed most recently at $120.07, in a 52-week range of $93.05 to $127.00.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest increase to 15.68 million shares from 14.84 million in the previous period. Shares closed Wednesday at $78.47, in a 52-week trading range of $71.39 to $109.23.
MannKind Corp. (NASDAQ: MNKD) saw the number of its shares short decrease slightly to 97.07 million. The previous reading was 97.76 million. The stock closed most recently at $0.47, in a 52-week range of $0.41 to $3.02. Note that MannKind is one of the most shorted Nasdaq stocks.
Alexion Pharmaceuticals Inc.’s (NASDAQ: ALXN) short interest decreased to 4.98 million, compared to the previous level of 5.37 million. Shares closed most recently at $127.16, in a 52-week range of $110.56 to $193.45.
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.